Oncology News | pharmaphorum

News

Roche adds to pipeline with Poseida, Kiniksa deals

Roche has announced a pair of licensing deals with Poseida Therapeutics and Kiniksa Pharmaceuticals that bolster its pipeline in cancer and inflammatory diseases.

News

Phase 3 lung cancer fail dents prospects of Ipsen, Servier's...

Ipsen and Servier's hopes of extending the uses for chemotherapy drug Onivyde have been knocked back by a failed phase 3 trial of the drug as a second-line therapy for small cell lung cance

News

Gilead Sciences' push into oncology is paying off, as Veklur...

Gilead Sciences' investment in oncology has started to provide a solid return, with sales of cancer therapies breaching the $500 million threshold for the first time in the second quarter.<

News

Doctor in white rubber protective gloves putting adhesive bandage on young man's arm after scratch on skin or injection of vaccine. First aid. Medical, pharmacy and healthcare concept. Closeup.

Roche scores phase 3 win for subcutaneous Tecentriq, eyes fi...

Roche's Tecentriq could become the first drug in the PD-1/PD-L1 inhibitor class to be approved in a subcutaneous formulation, after the new version matched the original intravenous formulat

News

AZ, Innate's checkpoint inhibitor monalizumab flunks phase 3...

AstraZeneca has abandoned a phase 3 trial of its experimental immuno-oncology candidate monalizumab in head and neck cancer, after an interim analysis suggested it was unlikely to show a be

News

Ipsen makes TCR play, grabbing two I-O therapies from Mareng...

Ipsen has joined the ranks of companies working on T cell receptor (TCR) therapies for cancer, paying $45 million upfront for rights to early-stage candidates developed by US biotech Mareng

Roche adds to pipeline with Poseida, Kiniksa deals

Phase 3 lung cancer fail dents prospects of Ipsen, Servier's...

Gilead Sciences' push into oncology is paying off, as Veklur...

Roche scores phase 3 win for subcutaneous Tecentriq, eyes fi...

AZ, Innate's checkpoint inhibitor monalizumab flunks phase 3...

Ipsen makes TCR play, grabbing two I-O therapies from Mareng...

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks